242 related articles for article (PubMed ID: 11223556)
1. [HBME-1 immunostaining in thyroid pathology].
Rigau V; Martel B; Evrard C; Rousselot P; Galateau-Salle F
Ann Pathol; 2001 Feb; 21(1):15-20. PubMed ID: 11223556
[TBL] [Abstract][Full Text] [Related]
2. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.
Miettinen M; Kärkkäinen P
Virchows Arch; 1996 Nov; 429(4-5):213-9. PubMed ID: 8972756
[TBL] [Abstract][Full Text] [Related]
3. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma.
Sack MJ; Astengo-Osuna C; Lin BT; Battifora H; LiVolsi VA
Mod Pathol; 1997 Jul; 10(7):668-74. PubMed ID: 9237176
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical localization of acidic and basic fibroblast growth factors in human benign and malignant thyroid lesions.
Kodama M; Daa T; Kashima K; Yokoyama S; Nakayama I; Noguchi S
Jpn J Clin Oncol; 1994 Apr; 24(2):66-73. PubMed ID: 7512670
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases].
Ziadi S; Trimeche M; Zermani R; Elmay A; Baltagi-Ben Jilani S
Tunis Med; 2005 May; 83(5):274-8. PubMed ID: 16044900
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
7. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536
[TBL] [Abstract][Full Text] [Related]
8. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
12. Blood group antigens in differentiated thyroid neoplasms.
González-Cámpora R; García-Sanatana JA; Jordà i Heras MM; Salaverri CO; Vázquez-Ramírez FJ; Argueta-Manzano OE; Galera-Davidson H
Arch Pathol Lab Med; 1998 Nov; 122(11):957-65. PubMed ID: 9822123
[TBL] [Abstract][Full Text] [Related]
13. Patterns of basement membrane laminin distribution in nonneoplastic and neoplastic thyroid tissue.
Campo E; Perez M; Charonis AA; Axiotis CA; Merino MJ
Mod Pathol; 1992 Sep; 5(5):540-6. PubMed ID: 1344818
[TBL] [Abstract][Full Text] [Related]
14. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
15. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
16. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
[TBL] [Abstract][Full Text] [Related]
19. Production of a novel monoclonal antibody, JT-95, which can detect antigen of thyroid carcinoma.
Takeyama H; Hosoya T; Sakurai K; Mori Y; Watanabe M; Kisaki H; Ohno T
Cancer Res; 1996 Apr; 56(8):1817-22. PubMed ID: 8620498
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
Bogdańska M; Górnicka B; Ziarkiewicz-Wróblewska B; Koperski L; Morton M; Wasiutyński A
Endokrynol Pol; 2006; 57(4):314-9. PubMed ID: 17006830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
